Universal Beteiligungs und Servicegesellschaft mbH Purchases 21,011 Shares of Bruker Corporation $BRKR

Universal Beteiligungs und Servicegesellschaft mbH increased its position in Bruker Corporation (NASDAQ:BRKR) by 3.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 573,164 shares of the medical research company’s stock after acquiring an additional 21,011 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Bruker were worth $18,622,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BRKR. Orbis Allan Gray Ltd bought a new stake in shares of Bruker in the 2nd quarter worth $192,735,000. AQR Capital Management LLC boosted its position in shares of Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares during the last quarter. Sculptor Capital LP increased its holdings in Bruker by 18.3% in the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after buying an additional 476,363 shares in the last quarter. Brown Advisory Inc. raised its position in Bruker by 13.9% in the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after buying an additional 336,026 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. lifted its stake in Bruker by 61.6% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock valued at $67,909,000 after acquiring an additional 796,510 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BRKR has been the subject of several research reports. TD Cowen reissued a “hold” rating on shares of Bruker in a report on Wednesday, January 7th. Rothschild Redb upgraded shares of Bruker to a “strong-buy” rating in a research note on Thursday, November 20th. Bank of America raised their price target on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. The Goldman Sachs Group started coverage on Bruker in a report on Tuesday, December 9th. They issued a “sell” rating and a $40.00 price objective for the company. Finally, Redburn Partners set a $60.00 target price on Bruker in a report on Thursday, November 20th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Bruker has an average rating of “Moderate Buy” and an average target price of $53.36.

Bruker Trading Down 3.4%

Shares of BRKR stock opened at $50.33 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91. The company has a market cap of $7.65 billion, a price-to-earnings ratio of -314.56, a PEG ratio of 6.85 and a beta of 1.17. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $59.40. The firm has a fifty day moving average price of $48.08 and a 200-day moving average price of $40.35.

Bruker (NASDAQ:BRKR) last released its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The company had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same period in the previous year, the business earned $0.60 earnings per share. Bruker’s quarterly revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, equities analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Monday, December 8th were paid a dividend of $0.05 per share. The ex-dividend date was Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s payout ratio is -125.00%.

Insider Activity at Bruker

In related news, VP Mark Munch sold 2,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total value of $98,400.00. Following the completion of the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $6,319,395.60. This represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the transaction, the director directly owned 35,212 shares in the company, valued at $1,373,268. This represents a 15.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 15,233 shares of company stock valued at $726,487 over the last three months. 27.30% of the stock is currently owned by insiders.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.